BiomX (PHGE)
(Delayed Data from AMEX)
$0.35 USD
-0.02 (-5.24%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $0.36 +0.01 (2.65%) 7:58 PM ET
4-Sell of 5 4
F Value C Growth B Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
PHGE 0.35 -0.02(-5.24%)
Will PHGE be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for PHGE based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PHGE
Here's Why BiomX (PHGE) Is a Great 'Buy the Bottom' Stock Now
BiomX (PHGE) Reports Positive Pulmonary Infection Treatment Data
PHGE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for PHGE
12 Health Care Stocks Moving In Tuesday's After-Market Session
BiomX Inc. Receives Notice of Non-Compliance with NYSE American Continued Listing Standards
BiomX to Present Phase 1b/2a Clinical Trial Data for BX004 at the 47th European Cystic Fibrosis Conference and at ASM Microbe 2024
BiomX Faces NYSE Delisting Over Equity Deficiency
12 Health Care Stocks Moving In Thursday's After-Market Session